A series of genetic changes, including germinal mutations in BRCA1/2, intratumoral BRCA1/2 mutations, BRCA1 promoter methylation, and other possible genetic causes, may indicate the loss of homologous recombination function in at least 50% of patients with ovarian cancer, according to TCGA data. This evidence concerns the gene BRCA1 and ovarian cancer.